+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anamorelin Market - Global Forecast 2026-2032- Product Image
Anamorelin Market - Global Forecast 2026-2032- Product Image
Sale

Anamorelin Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6152047
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anamorelin Market is projected to reach USD 150.69 Million in 2026. It is expected to continue growing at a CAGR of 10.26%, reaching USD 271.51 Million by 2032.

Anamorelin: Executive Summary and Strategic Context

Anamorelin is an investigational ghrelin-receptor agonist designed to address cancer-associated weight loss and muscle wasting. Its clinical relevance is tied to the growing need for supportive-care interventions that may improve nutritional status, physical function, and treatment resilience alongside anticancer therapy. Evaluation should distinguish changes in body weight from clinically meaningful gains in skeletal muscle, strength, quality of life, and treatment continuity.

Shifting Standards in Cancer-Associated Wasting Care

The management landscape is moving toward earlier identification of cachexia, multidimensional assessment, and coordinated care involving oncology, nutrition, rehabilitation, and palliative-care specialists. Drug development is increasingly judged against patient-centered outcomes rather than weight change alone. Regulatory expectations, safety monitoring, comorbidity management, and integration with exercise and dietary support will strongly influence adoption pathways for anamorelin.

Artificial Intelligence Strengthens Patient Identification and Evidence Generation

Artificial intelligence can support anamorelin development and clinical use by identifying patients at risk of cachexia from electronic records, imaging, laboratory results, and longitudinal treatment data. Predictive models may improve trial recruitment, stratify disease severity, and detect response patterns across cancer types. However, algorithmic bias, inconsistent data quality, explainability, privacy, and prospective validation remain essential safeguards; AI should augment clinician judgment rather than replace it.

Regional Insights: Diverse Access and Evidence Requirements

North America emphasizes evidence generation, specialist oncology pathways, and payer scrutiny, while Latin America faces varied diagnostic capacity and uneven access to supportive cancer care. Europe places strong weight on health-technology assessment, integrated clinical guidelines, and cross-country reimbursement differences. The Middle East is characterized by concentrated specialist services alongside heterogeneous infrastructure, and Africa requires scalable screening, nutrition support, and workforce development. Asia-Pacific combines advanced oncology systems in some markets with substantial variation in affordability, regulatory processes, and rural access.

Group Insights: Policy Alignment Across Multinational Blocs

ASEAN priorities include harmonizing regulatory approaches and improving access across diverse health systems. BRICS members span major oncology populations but differ substantially in reimbursement, local evidence requirements, and clinical capacity. The European Union benefits from shared scientific and regulatory structures while retaining national decisions on funding. G7 systems generally have mature oncology infrastructure and demanding comparative-evidence standards. GCC countries often have centralized procurement and specialist care hubs, whereas NATO members reflect varied health-system models and should not be treated as a uniform commercial or clinical market.

Country Insights: Local Pathways Shape Clinical Uptake

Australia and Canada are likely to emphasize specialist evaluation, evidence-based reimbursement, and geographically distributed care. Brazil, Mexico, India, China, and Russia require attention to regional disparities, affordability, and local regulatory or evidence pathways. France, Germany, Italy, Spain, and the United Kingdom combine established oncology services with country-specific assessment, prescribing, and funding processes. Japan and South Korea have advanced clinical infrastructures and distinctive regulatory and reimbursement requirements. In the United States, uptake would depend on robust clinical evidence, physician adoption, payer coverage, and integration with existing cachexia management.

Priorities for Leaders: Build Evidence Around Meaningful Patient Benefit

Industry leaders should prioritize randomized evidence that measures muscle mass, physical function, symptoms, quality of life, and treatment continuity in clearly defined patient populations. Partnerships with oncology networks can improve identification and referral, while companion nutrition and rehabilitation pathways can support responsible use. Regional launch planning should account for regulatory evidence standards, health-technology assessment, affordability, pharmacovigilance, and clinician education. AI initiatives should begin with validated, transparent tools and strong governance. Clear communication should avoid equating weight gain alone with restoration of health.

Research Methodology: Evidence-Led Executive Assessment

This executive summary applies a structured qualitative assessment of anamorelin’s therapeutic context, clinical evidence needs, healthcare-system conditions, and geographic variation. The analysis prioritizes peer-reviewed clinical research, regulatory and guideline materials, health-technology assessment principles, and established oncology and cachexia frameworks. Regional, group, and country observations are presented as contextual considerations rather than market estimates. No market sizing, market-share, forecasting, or company-specific claims are included.

Conclusion: Clinical Value Depends on Integrated Cachexia Management

Anamorelin’s strategic significance rests on whether it can deliver durable, clinically meaningful benefits for people with cancer-associated wasting within coordinated supportive care. Success will depend on high-quality evidence, appropriate patient selection, safety oversight, equitable access, and integration with nutrition, exercise, symptom management, and anticancer treatment. Leaders should therefore evaluate the therapy through patient outcomes and health-system value, not body-weight change in isolation.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anamorelin Market, by Product Type
7.1. Introduction
7.2. Branded Anamorelin
7.3. Anamorelin API
8. Anamorelin Market, by Application
8.1. Introduction
8.2. Non-Small Cell Lung Cancer
8.3. Pancreatic Cancer
8.4. Colorectal Cancer
8.5. Gastric Cancer
9. Anamorelin Market, by End User
9.1. Introduction
9.2. Hospitals
9.3. Oncology Clinics
9.4. Specialty Cancer Centers
10. Anamorelin Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.2.1. Hospital Pharmacies
10.2.2. Retail Pharmacies
10.2.3. Specialty Pharmacies
10.3. Online
11. Anamorelin Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. Europe
11.4. North America
11.5. Latin America
11.6. Africa
11.7. Middle East
12. Anamorelin Market, by Group
12.1. Introduction
12.2. NATO
12.3. G7
12.4. BRICS
12.5. European Union
12.6. ASEAN
12.7. GCC
13. Anamorelin Market, by Country
13.1. Introduction
13.2. United States
13.3. China
13.4. Japan
13.5. India
13.6. Germany
13.7. Canada
13.8. United Kingdom
13.9. Brazil
13.10. Australia
13.11. Mexico
13.12. France
13.13. South Korea
13.14. Italy
13.15. Russia
13.16. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Helsinn Group
15.2. Ono Pharmaceutical Co., Ltd.
15.3. Fosun Pharmaceutical A.G.
15.4. Mundipharma Pharmaceuticals Limited
15.5. Angelini Pharma S.p.a.
15.6. Merck & Co., Inc.
15.7. BIAL - Portela & Ca. S.A.
15.8. JieJie Group Co.,Ltd
15.9. Artelo Biosciences, Inc.
15.10. Chugai Pharmaceutical Co., Ltd.
15.11. Gen Ilaç
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Anamorelin Market, Years Considered for the Study
FIGURE 2. Global Anamorelin Market, Research Design
FIGURE 3. Global Anamorelin Market, Research Framework
FIGURE 4. Global Anamorelin Market, Data Triangulation
FIGURE 5. Global Anamorelin Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Anamorelin Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Anamorelin Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Anamorelin Market Size, by Application, 2025 vs 2032 (%)
FIGURE 9. Global Anamorelin Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Anamorelin Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Anamorelin Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Anamorelin Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Anamorelin Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Anamorelin Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Anamorelin Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Anamorelin Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Anamorelin Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Anamorelin Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Anamorelin Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Anamorelin Market Segmentation & Coverage
TABLE 2. Global Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 3. Global Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Branded Anamorelin Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Branded Anamorelin Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Branded Anamorelin Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Anamorelin API Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Anamorelin API Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Anamorelin API Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 11. Global Non-Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Non-Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Non-Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Pancreatic Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Pancreatic Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Pancreatic Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Gastric Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Gastric Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Gastric Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 24. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Oncology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Oncology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Oncology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Specialty Cancer Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Specialty Cancer Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Specialty Cancer Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 34. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Specialty Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Specialty Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Specialty Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Anamorelin Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Asia-Pacific Anamorelin Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Asia-Pacific Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 52. Asia-Pacific Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 53. Asia-Pacific Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 56. Europe Anamorelin Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Europe Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 58. Europe Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 59. Europe Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 60. Europe Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 61. Europe Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 62. North America Anamorelin Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. North America Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 64. North America Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 65. North America Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 66. North America Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 67. North America Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 68. Latin America Anamorelin Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Latin America Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 70. Latin America Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 71. Latin America Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 72. Latin America Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 73. Latin America Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 74. Africa Anamorelin Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Africa Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 76. Africa Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 77. Africa Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Africa Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 79. Africa Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 80. Middle East Anamorelin Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Middle East Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 82. Middle East Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 83. Middle East Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. Middle East Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 85. Middle East Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 86. Global Anamorelin Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. NATO Anamorelin Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. NATO Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 89. NATO Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 90. NATO Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. NATO Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 92. NATO Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 93. G7 Anamorelin Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. G7 Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 95. G7 Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 96. G7 Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 97. G7 Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. G7 Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 99. BRICS Anamorelin Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. BRICS Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. BRICS Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 102. BRICS Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. BRICS Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. BRICS Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 105. European Union Anamorelin Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. European Union Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. European Union Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 108. European Union Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 109. European Union Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. European Union Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 111. ASEAN Anamorelin Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. ASEAN Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 113. ASEAN Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 114. ASEAN Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. ASEAN Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 116. ASEAN Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 117. GCC Anamorelin Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. GCC Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 119. GCC Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 120. GCC Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. GCC Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. GCC Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 123. Global Anamorelin Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. United States Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 125. United States Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 126. United States Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 127. United States Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. United States Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. United States Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 130. China Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 131. China Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. China Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 133. China Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. China Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. China Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 136. Japan Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 137. Japan Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 138. Japan Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 139. Japan Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. Japan Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. Japan Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 142. India Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 143. India Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 144. India Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 145. India Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. India Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 147. India Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 148. Germany Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 149. Germany Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 150. Germany Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 151. Germany Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. Germany Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. Germany Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 154. Canada Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 155. Canada Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 156. Canada Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 157. Canada Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. Canada Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. Canada Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 160. United Kingdom Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 161. United Kingdom Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 162. United Kingdom Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 163. United Kingdom Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. United Kingdom Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 165. United Kingdom Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 166. Brazil Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 167. Brazil Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. Brazil Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 169. Brazil Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. Brazil Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 171. Brazil Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 172. Australia Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 173. Australia Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 174. Australia Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 175. Australia Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. Australia Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. Australia Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 178. Mexico Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 179. Mexico Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. Mexico Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 181. Mexico Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Mexico Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. Mexico Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 184. France Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 185. France Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 186. France Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 187. France Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. France Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 189. France Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 190. South Korea Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 191. South Korea Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 192. South Korea Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 193. South Korea Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. South Korea Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. South Korea Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 196. Italy Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 197. Italy Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 198. Italy Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 199. Italy Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Italy Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 201. Italy Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 202. Russia Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 203. Russia Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 204. Russia Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 205. Russia Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. Russia Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 207. Russia Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 208. Spain Anamorelin Market Size, 2017-2032 (USD Million)
TABLE 209. Spain Anamorelin Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 210. Spain Anamorelin Market Size, by Application, 2017-2032 (USD Million)
TABLE 211. Spain Anamorelin Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. Spain Anamorelin Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 213. Spain Anamorelin Market Size, by Offline, 2017-2032 (USD Million)
TABLE 214. Global Anamorelin Market Share, by Key Player, 2025
TABLE 215. Global Anamorelin Market, Key Experts

Companies Mentioned

  • Helsinn Group
  • Ono Pharmaceutical Co., Ltd.
  • Fosun Pharmaceutical A.G.
  • Mundipharma Pharmaceuticals Limited
  • Angelini Pharma S.p.a.
  • Merck & Co., Inc.
  • BIAL - Portela & Ca. S.A.
  • JieJie Group Co.,Ltd
  • Artelo Biosciences, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Gen Ilaç

Related Topics

Related Reports

Somatostatin Analogs Market - Global Forecast 2026-2032 - Product Image

Somatostatin Analogs Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Human Chorionic Gonadotropin Market - Global Forecast 2026-2032 - Product Image

Human Chorionic Gonadotropin Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 328 Pages
  • Global
From
Semaglutide - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Semaglutide - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From
Insulin Pumps Market Report by Product Type, Distribution Channel, and Region 2026-2034 - Product Image

Insulin Pumps Market Report by Product Type, Distribution Channel, and Region 2026-2034

  • Report
  • 146 Pages
  • Global
From

About the Market

Anamorelin is a drug used to treat endocrine and metabolic disorders. It is a ghrelin agonist, meaning it stimulates the release of growth hormone from the pituitary gland. Anamorelin is used to treat cachexia, a condition characterized by muscle wasting and weight loss, which is often seen in patients with cancer or chronic kidney disease. It is also used to treat growth hormone deficiency in adults. Anamorelin is available in tablet form and is taken orally once daily. It is generally well tolerated, with the most common side effects being nausea, vomiting, and diarrhea. The anamorelin market is a growing one, with many companies developing and marketing the drug. Some of these companies include Helsinn Healthcare, Eisai Co., Ltd., and Novartis AG. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.